6月2日，Abivax S.A.盘后上涨31.08%，报170.0美元/股，成交额970.37万美元。
Abivax S.A.所在的生物科技行业中，个股中，Revolution Medicines涨0.53%，艾伯维公司跌0.53%，吉利德科学持平，安进涨0.46%，再生元制药公司涨0.22%。
Abivax S.A.是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，并正在开发用于克罗恩病。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.